液体活检在非小细胞肺癌中的应用

随着精准医疗和个体化治疗在肺癌领域中的发展，对肿瘤分子生物学特性进行实时监测的要求越来越高。“液体活检”以其标本获取简便、创伤小、重复性高的特点在近年来引起了广泛关注。在所有肺癌患者中，非小细胞肺癌（ non small cell lung cancer，NSCLC）占85%~90%，针对NSCLC，特别是肺腺癌驱动突变的发现及相应靶向治疗的成功应用极大地改写了肺癌治疗的篇章，与此同时也对NSCLC相关分子生物学标志物的实时检测提出了更高的要求。本文以液体活检标志物的检测为起点，就其在NSCLC患者中的临床应用做一综述。

The utility of liquid biopsy in NSCLC

With the rapid development of precision medicine and individual therapy in lung cancer,the demand for real-time monitoring of tumor molecular characteristic has been increased."Liquid biopsy" has attracted extensive attention for its convenience,minimal invasiveness and high reproducibility in recent years. About 85% ~90% of lung cancer patients are identified as NSCLC,the treatment decision of NSCLC has been changed a lot since the discovery of driver mutations and the successful application of targeted therapy,especially in lung adenocarcinoma. Meanwhile higher demand for real-time monitoring of molecular biomarkers in NSCLC is required. This review discusses the de-tection of biomarkers in liquid biopsy and its clinical application in NSCLC patients.